Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon α

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3696-3701

  Vaishampayan, Ulka ^a   Abrams, Judith ^b   Darrah, Denise ^c   Jones, Vicky ^c   Mitchell, Malcolm S ^a,d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MELACINE; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; BONE MARROW; CANCER GROWTH; CANCER SURVIVAL; CELL LINE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DOSE CALCULATION; DRUG RESPONSE; DRUG TOLERANCE; FLU LIKE SYNDROME; FREEZE DRYING; GRANULOMA; HUMAN; IMMUNOTHERAPY; KIDNEY FUNCTION; LIVER FUNCTION; MELANOMA; MELANOMA CELL; METASTASIS; PAIN; PRIORITY JOURNAL; TIME; TOXICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERFERON ALFA-2B; LUNG NEOPLASMS; LYMPHATIC METASTASIS; LYMPHOKINES; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036895111     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Greenlee, R. T., Hill-Harmon, M., and Murray, T. Cancer Statistics 2001. CA Cancer J. Clin., 51: 15-36, 2001.
2. Mitchell, M. S., Kan-Mitchell, J., Kempf, R. A., Harel, W., Shau, H., and Lind, S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res., 48: 5883-5893, 1988.
3. Mitchell, M. S., Harel, W., Kempf, R. A., Hu, E., Kan-Mitchell, L., Boswell, W. D., Dean, G., and Stevenson, L. Active specific immunotherapy for melanoma. J. Clin. Oncol., 8: 856-869, 1990.
4. Mitchell, M. S., Darrah, D., and Stevenson, L. Therapy of melanoma with allogeneic lysates with or without interferon-α. Cancer Investig., in press, 2002.
5. Creagan, E. T., Ahmann, D. L., Frytak S., Long, H. J., Chang, M. N., and Itri, L. M. Three consecutive Phase Il studies of recombinant interferon α2a in advanced malignant melanoma. Cancer (Phila.), 59: 638-646, 1987.
6. Hernberg, M., Pyrhonen, S., and Muhonen, T. Regimens with or without interferon-α as treatment for metastatic melanoma and renal cell carcinoma: An overview of randomized trials. J. Immunother., 22: 145-154, 1999.
7. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E, C., and Blum, R, H. IFN adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol., 14: 7-17, 1996.
8. Mitchell, M. S., Jakowatz, J., Harel, W., Dean, G., Stevenson, L., Boswell, W. D., and Groshen, S. Increased effectiveness of interferon α-2b following active specific immunotherapy for melanoma. J. Clin. Oncol., 12: 402-411, 1994.
9. North, R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor induced suppressor cells. J. Exp. Med., 55: 1063-1074, 1982.
10. Huang, X. Q., Mitchell. M. S., Liggett, P. E., Murphree, A. L., and Kan-Mitchell, J. Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients. Cancer Immunol. Immunother., 38: 399-405, 1994.
11. Berd, D., Maguire. H. C., Jr., and Mastrangelo, M. J. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res., 44: 5439-5443, 1984.
12. Hengst, J. C. D., Kempf, R. A., Kan-Mitchell, J., Pham, A. T. H., Grunberg, S. M., Kortes, V. L., and Mitchell, M. S. Immunological effects of recombinant interferon-α2 in cancer patients. J. Biol. Resp. Modif., 2: 516-527, 1983.
13. Miller. A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.). 47: 207-214, 1981.
14. Mitchell, M. S., Harel, W., and Groshen, S. Association of HLA phenotype with clinical response to active specific immunotherapy of melanoma. J. Clin. Oncol., 10: 1158-1168, 1992.
15. Sosman, J. A., Unger, J. M., Liu, P. Y., Flaherty. L. E., Park, M. S., Kempf, R. A., Thompson, J. A., Terasaki, P. I., and Sondak, V. K. Adjuvant immunotherapy of resected intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA Class I antigen expression on outcome. J. Clin. Oncol., 20: 2067-2075, 2002.
16. Keilholz, U., Scheibenbogen C., Sommer M., Pritsch, M., and Geuke, A. M. Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy. Melanoma Res., 6: 173-178, 1996.
17. Proebstle, T. M., Scheibenbogen, C., Sterry, W., and Keilholz, U. Phase II study of dacarbazine, cisplatin, interferon-α and high dose interleukin-2 in poor risk metastatic melanoma. Eur. J, Cancer, 32: 1530-1533, 1996.
18. Dillman, R. O., Soori, G., Wiemann, M. C., Schulof, R., Dobbs, T. W., Ruben, R. H., DePriest, C. B., and Church, C. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-α, intravenouscombination chemotherapy and oral tamoxifen in the treatment of metastatic melanoma: Final results of Cancer Biotherapy Research Group 94-11. Cancer Biother. Radiopharm., 15: 487-494, 2000.
19. Daponte, A., Ascierto, P. A., Gravina, A., Melucci, M. T., Palmieri, G., Comella, P., Cellerino, R., DeLena, M., Marini, G., and Comella, G. Italian Cooperative Oncology Group. Cisplatin, dacarbazine and fotemustine plus interferon-α in patients with advanced malignant melanoma. A multicenter Phase II study of the Italian Cooperative Oncology Group. Cancer (Phila.), 89: 2630-2636, 2000.
20. Legha, S. S., Ring, S., Eton, O., Bedikian, A., Buzaid, A. C., Plager, C., and Papadoulos, N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine interferon-α and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol., 16: 1752-1759, 1998.
21. Legha, S. S. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon α and chemotherapy. Semin. Oncol., 24: S39-S43, 1997.
22. Mitchell, M. S. Allogeneic melanoma vaccines for treatment and prevention of recurrence. In: F. G. Haluska (ed.), Biology and Treatment of Melanoma, in press. New York: Kluwer Academic/Plenum, 2002.
23. Elliott, G. T., McLeod, R. A., Perez, J., and Von Eschen, K. B. Interim results of a Phase II multicenter clinical trial evaluating the activity of a therapeutic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin. Surg. Oncol., 9: 264-272, 1993.